Allantoin ameliorates chemically-induced pancreatic β-cell damage through activation of the Imidazoline I3 receptors

Marie Amitani, Kai-Chun Cheng, Akihiro Asakawa, Haruka Amitani, Timothy Sean Kairupan, Nanami Sameshima, Toshiaki Shimizu, Teruto TH Hashiguchi, Akio Inui

Objective: Allantoin is the primary active compound in yams (Dioscorea spp.). Recently, allantoin has been demonstrated to activate imidazoline 3 (I3) receptors located in pancreatic tissues. Thus, the present study aimed to investigate the role of allantoin in the effect to improve damage induced in pancreatic β-cells by streptozotocin (STZ) via the I3 receptors. Research Design and Methods: The effect of allantoin on STZ-induced apoptosis in pancreatic β-cells was examined using the ApoTox-Glo triplex assay, live/dead cell double staining assay, flow cytometric analysis, and Western blottings. The potential mechanism was investigated using KU14R: an I3 receptor antagonist, and U73122: a phospholipase C (PLC) inhibitor. The effects of allantoin on serum glucose and insulin secretion were measured in STZ-treated rats. Results: Allantoin attenuated apoptosis and cytotoxicity and increased the viability of STZ-induced β-cells in a dose-dependent manner; this effect was suppressed by KU14R and U73112. Allantoin decreased the level of caspase-3 and increased the level of phosphorylated B-cell lymphoma 2 (Bcl-2) expression detected by Western blotting. The improvement in β-cells viability was confirmed using flow cytometry analysis. Daily injection of allantoin for 8 days in STZ-treated rats significantly lowered plasma glucose and increased plasma insulin levels. This action was inhibited by treatment with KU14R. Conclusion: Allantoin ameliorates the damage of β-cells induced by STZ. The blockade by pharmacological inhibitors indicated that allantoin can activate the I3 receptors through a PLC-related pathway to decrease this damage. Therefore, allantoin and related analogs may be effective in the therapy for β-cell damage.
ALLANTOIN AMELIORATES CHEMICALLY-INDUCED PANCREATIC β-CELL DAMAGE THROUGH ACTIVATION OF THE IMIDAZOLINE I3 RECEPTORS

Marie Amitani¹, Kai-Chun Cheng¹, Akihiro Asakawa¹, Haruka Amitani¹, Timothy Sean Kairupan¹, Nanami Sameshima¹, Toshiaki Shimizu², Teruto Hashiguchi², Akio Inui¹

1. Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
2. Department of Laboratory and Vascular Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

Corresponding author
Akio Inui
Address: Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan
Telephone: +81-99-275-5751
Fax: +81-99-275-5749
E-mail address: inui@m.kufm.kagoshima-u.ac.jp
Abstract

Objective: Allantoin is the primary active compound in yams (Dioscorea spp.). Recently, allantoin has been demonstrated to activate imidazoline 3 (I3) receptors located in pancreatic tissues. Thus, the present study aimed to investigate the role of allantoin in the effect to improve damage induced in pancreatic β-cells by streptozotocin (STZ) via the I3 receptors.

Research Design and Methods: The effect of allantoin on STZ-induced apoptosis in pancreatic β-cells was examined using the ApoTox-Glo triplex assay, live/dead cell double staining assay, flow cytometric analysis, and Western blottings. The potential mechanism was investigated using KU14R: an I3 receptor antagonist, and U73122: a phospholipase C (PLC) inhibitor. The effects of allantoin on serum glucose and insulin secretion were measured in STZ-treated rats.

Results: Allantoin attenuated apoptosis and cytotoxicity and increased the viability of STZ-induced β-cells in a dose-dependent manner; this effect was suppressed by KU14R and U73112. Allantoin decreased the level of caspase-3 and increased the level of phosphorylated B-cell lymphoma 2 (Bcl-2) expression detected by Western blotting. The improvement in β-cells viability was confirmed using flow cytometry analysis. Daily injection of allantoin for 8 days in STZ-treated rats significantly lowered plasma glucose and increased plasma insulin levels. This action was inhibited by treatment with KU14R.

Conclusion: Allantoin ameliorates the damage of β-cells induced by STZ. The blockade by pharmacological inhibitors indicated that allantoin can activate the I3 receptors through a PLC-related pathway to decrease this damage. Therefore, allantoin and related analogs may be effective in the therapy for β-cell damage.

Keywords: Allantoin; Imidazoline 3 receptor; Pancreatic β-cell; Streptozotocin; PLC-related
pathway
Introduction

Allantoin is the primary active compound in yams (Dioscorea spp.) (Sagara et al. 1989). In the pharmaceutical industry, yams are widely used to prevent inflammation and ulcers because they contain ureides such as allantoin (Lee et al. 2010). Dioscoreaceae plants have also been shown to improve metabolic and diabetic disorders (Chang et al. 2005; Sato et al. 2009; Wang et al. 2012). Several pathogenic processes are involved in the development of diabetes, including the destruction of pancreatic β-cells that results in insulin resistance (Cnop et al. 2005). Autoimmunity is one of the main causes of diabetes type 1 via damage of the insulin-producing β-cells in the pancreas (American Diabetes 2010). In addition to insulin resistance, increased apoptosis and a significant reduction in the number of β-cells have been implicated in type 2 diabetes (Butler et al. 2003). Thus, prevention of pancreatic damage and the development of therapeutic strategies to protect β-cells have been introduced as a major target for the management of diabetes (Mandrup-Poulsen 2001).

The imidazoline receptor is an orphan receptor with three subtypes. The imidazoline 1 (I1) receptors act to lower blood pressure (Ernsberger et al. 1995), whereas the imidazoline 2 (I2) receptors serve as an allosteric binding site for monoamine oxidase and are known to be involved in pain modulation, neuroprotection and increased glucose uptake in muscle cells (Li & Zhang 2011; Lui et al. 2010). The imidazoline 3 (I3) receptors play an important role in regulating insulin secretion from β-cells in the pancreas (Head & Mayorov 2006).

Guanidine derivates can bind to the imidazoline receptors (Dardonville & Rozas 2004). Allantoin, a guanidine derivative, has been shown to activate the I1 receptors to attenuate hyperlipidemia, improve hepatic steatosis and act as an antihypertensive agent (Chen et al. 2014a;
Yang et al. 2012). Additionally, allantoin also increases glucose uptake in muscle cells via the I2 receptors (Chen et al. 2012; Lin et al. 2012). A recent study demonstrated that allantoin was able to bind to the I3 receptors, resulting in the lowering of blood glucose due to increased plasma insulin levels (Tsai et al. 2014). Moreover, insulinotropic agents such as glucagon-like peptide-1, an incretin derived from the transcription product of the proglucagon gene, can also protect β-cells from apoptosis (Cernea 2011; Liu et al. 2012). Thus, we speculated that allantoin may play a role in pancreatic β-cell protection via the I3 receptor. The present study aimed to identify the role of allantoin in improving damage in pancreatic β-cells induced by a low dose of streptozotocin (STZ).

Material and Methods

Animals

Male Wistar rats weighing 320 – 340 g obtained from Japan SLC, Inc (Shizuoka, Japan), were maintained in an environment under a 12 hour light/12 hour dark cycle with a controlled room temperature at the animal center of Kagoshima University (Kagoshima, Japan). Food and tap water were provided ad libitum with free access. All procedures in this study were approved by the Ethics Committee for Animal Care and Use of Kagoshima University (IRB approval number MD14059).

Islet isolation and primary culture

Following a previous method (Shewade et al. 1999), pancreatic islets were removed from rat pancreases. The pancreases were incised into smaller portions and digested with 1 mg/mL collagenase (Roche; Basel, Switzerland) for 10 minutes. The digested samples were washed two times with RPMI 1640 medium (Sigma; St. Louis, MO, USA) containing 10% fetal bovine serum
FBS (Thermo; Waltham, MA, USA) to inactivate the collagenase. The isolated pancreatic islets were cultured in RPMI 1640 supplemented with 1% penicillin and streptomycin (Life Technology; Carlsbad, CA, USA), 1% amphotericin B (Sigma; St. Louis, MO, USA) and 10% FBS. The primary culture was incubated (37°C with 5% CO\textsubscript{2}) for 48 h. After the incubation period, the primary culture was divided into 6-well plates for Live/Dead double staining assay, 96-well plates for the ApoTox-Glo Triplex assay, and 12-well plates for annexin and flow cytometry analysis.

_Treatment of cells with reagents_

The primary cultured cells were devided into 6-well plates. The medium was removed, and the cells were washed once with phosphate-buffered saline (PBS). RPMI 1640 medium containing 25 mM glucose was added to each well with 5 mM STZ (Sigma-Aldrich, St. Louis, MO, USA) and incubated for 6 h to induce cell apoptosis. To know the role of allantoin in the protection of pancreatic β-cells against STZ, allantoin (Sigma-Aldrich, St. Louis, MO, USA) pretreatment at various doses was provided before 30 minutes prior to the addition of 5 mM STZ and incubated for 6 h. To identify the signaling pathway of allantoin in β-cells, 1 µM KU14R (Santa Cruz Biotechnology; Santa Cruz, CA, USA): an I\textsubscript{3} binding site antagonist, or 1 µM U73122 (TOCRIS; Bristol, UK): the phospholipase C (PLC) inhibitor were provided before 30 minutes prior to the addition of allantoin as previously described before (Yang et al., 2015). All the medium was removed, and the cells were washed three times with PBS prior to processing for the evaluation of morphology.

_Live/Dead double staining assay_

Using the Live/Dead assay kit (Life Technology; Carlsbad, CA, USA), we stained β-cells to
distinguish the living cells from dead cells according to the manufacturer’s instruction. We added 100 µl of Live/Dead solution to the samples and incubated them for 15 min at room temperature. Then, the staining solution was removed and the samples were viewed under a fluorescence microscope (LSM700)(Zeiss, Jena, Germany). Living cells were detected at green fluorescence, whereas dead cells were detected at red fluorescence.

**ApoTox-Glo Triplex Assay**

The β-cells were seeded into 96-well plates at a total density of 1x10^4 cells per well. Each well contained 200 µl RPMI 1640 medium and the test compound where appropriate. ApoTox-Glo Triplex Assay (Promega; Madison, WI, USA) was used according to the manufacturer’s instructions to measure the β-cells’ viability, cytotoxicity, and apoptosis. After 24 hours the Viability/Cytotoxicity reagent, containing both the GF-AFC substrate and the bis-AAF-R110 substrate, was added to all wells and incubated for 30 min. Caspase-Glo 3/7 was added to the wells and mixed briefly for 30 s, then incubated for 30 min at room temperature. Fluorescence was measured at 380EX/510EM to assess viability, 485EX/520EM to assess cytotoxicity, and luminescence was measured to assess apoptosis.

**Annexin V/PI staining and flow cytometry analysis**

The primary cultured β-cells were divided into 12-well plates and categorized into four groups. Each group was treated with different reagents as follows: 1) 5 mM STZ; 2) 5 mM STZ and 100 µM allantoin; 3) 5 mM STZ, 1 µM KU14R and 100 µM allantoin; and 4) control. The cells were incubated with the reagents for 48 h. Then, the cells were collected and the apoptotic cells in each group were quantified using Annexin V-PI staining (Life Technology; Carlsbad, CA, USA) and
analyzed using flow cytometer based on the previously described method (Luo et al. 2014).

**Western blotting analysis**

Western blotting analysis was performed to determine caspase-3 and Bcl-2 expression. The β-cells were pre-cultured with 5 mM STZ for 6 h prior to the addition of 100 µM allantoin with or without 1 µM KU14R or vehicle for 30 min. The β-cells were washed with ice-cold PBS and incubated for 15 min to allow lysis to occur. The protein concentration was measured by BCA protein assay (Thermo Fisher Scientific Inc., USA). The protein samples were filtered and separated by SDS-PAGE (Polyacrylamide Gel Electrophoresis) (10% acrylamide gel) using the Bio-Rad Trans-Blot system and were transferred to polyvinylidene difluoride membranes. The membrane was blocked with 5% non-fat milk in Tris-buffered saline containing 0.1% Tween 20 (TBS-T). The membrane was incubated for 2 h and washed with TBS-T and hybridized overnight with primary antibodies, caspase-3 (Merk Millpore, USA) and Bcl-2 (Cell signaling Technology, Danvers, MA, USA), diluted with a suitable concentration of TBS. Incubation with secondary antibodies and the detection of the antigen-antibody complex was performed using an ECL kit (Thermo Fisher Scientific Inc., USA). The bands densities were quantified using a laser densitometer.

**Glucose and insulin levels in STZ-treated rats**

The induction of pancreatic cell damage was accomplished by injecting 45 mg/kg STZ dissolved in 10 mM Na-citrated buffer intraperitoneally. STZ-treated rats with blood glucose above 200 mg/dl at 7 days post-injection were included in the group. Total of 24 rats were divided into three groups as follows: Control (STZ) (n = 8), STZ + allantoin (n = 8), STZ + KU14R + allantoin (n = 8). The third groups was treated with an intravenous injection of 8 mg/kg/day KU14R; the first
and second groups were treated with the same volume of vehicle injected intravenously. After 30 min of KU14R injection, the second and third groups received 10 mg/kg/day of allantoin intravenously. The first group was injected the same volume of vehicle intravenously. The experiments were performed for 8 days. The blood samples were obtained from tail vein everyday. The plasma glucose levels were measured everyday, and the plasma insulin levels were measured on day 0, 4, 6, 8.

Statistical analysis

Statistical analyses were performed using SPSS software (SPSS, Inc., Chicago, IL, USA). An analysis of variance (ANOVA) with Tukey’s test to determine significant differences were used to compare multiple treatment groups. Data are presented as the mean ± standard error (S.E.) based on the number (n) of samples in each group. Statistical significance was set at $p < 0.05$.

Results

Allantoin decreased streptozocin-induced cytotoxicity and apoptosis in β-cells

Viable β-cells were significantly reduced in the STZ treated group, while cell toxicity and apoptosis were significantly increased compared to the control. In contrast, treatment with allantoin at various concentrations (1 μM, 10 μM, and 100 μM) significantly increased cell viability, and decreased cytotoxicity and apoptosis induced by STZ in a dose-dependent manner. These results suggest that allantoin attenuated STZ-induced cell damage (Fig 1).

Allantoin-induced increase in β-cell viability was blocked by an I3 antagonist
I3 receptors located on pancreatic β-cells are known to stimulate insulin secretion (Chen et al. 2014b; Dardonville & Rozas 2004). Thus, the effect of allantoin on imidazoline I3 receptors was investigated using KU14R, an I3 specific antagonist, in the Apo Tox triplex assay. The effect of allantoin was inhibited by KU14R (Fig 2).

**Allantoin increased the viability of STZ-treated β-cells**

Exposure of the β-cells to 5 mM STZ induced apoptosis based on the increase in red fluorescence compared to the control group. The β-cell viability was increased by the addition of allantoin, shown by the marked decrease in red fluorescence emitted by EthD-1, which can bind to the DNA of the dead cells. We found that pretreatment with 1µM KU14R for 30 minute resulted in the increased EthD-1 binding, thereby reducing the action of allantoin (Fig 3).

**Allantoin decreased the β-cell apoptosis percentage detected by flow cytometry**

Viable cells are located in the lower left quadrant in the flow cytometric analysis. Treatment with 5 mM STZ for 6 h increased the percentage of apoptotic cells to 45.5 %, indicated by the increased number of cells in the lower right quadrant. Allantoin reversed this effect and decreased the percentage of apoptotic cells to 32.7%, as shown by movement of the cell population from the lower right quadrant to the lower left quadrant. Co-treatment with KU14R blocked the action of allantoin and induce apoptosis to 53.9 % (Fig 4).

**Allantoin-induced cell protective effect involved phospholipase C**

To test whether the protective effect of allantoin involves the PLC pathway, we applied U73122: a PLC inhibitor. U73122 attenuated the protective effect of allantoin in β-cells (Fig 5).
Allantoin decreased caspase-3 and increased Bcl-2 expression

Caspase-3 and Bcl-2 are associated with the process of cell death. Caspase-3 is known to play a central role in cell apoptosis, whereas Bcl-2 regulates cell death. We used Western blotting analysis to detect the expression of these two regulatory proteins. In the STZ-treated group, the expression level of caspase-3 was significantly increased, while the Bcl-2 level was significantly decreased. Allantoin significantly suppressed the expression of caspase-3 and significantly increased the expression of Bcl-2. In contrast, KU14R significantly inhibited these actions of allantoin (Fig 6).

Plasma glucose levels in rats treated with STZ, allantoin, and KU14R

Plasma glucose levels were increased following intraperitoneal injection of STZ. Treatment with allantoin significantly lowered the blood glucose levels in STZ-treated rats. This effect of allantoin was countered by combined treatment with KU14R (Fig 7).

Plasma insulin levels in rats treated with STZ, allantoin, and KU14R

Plasma insulin levels were decreased following intraperitoneal injection of STZ. Treatment with allantoin significantly improved the plasma insulin levels. In contrast, co-treatment with KU14R countered this effect of allantoin (Fig 8).

Discussion

Allantoin is known to bind to the imidazoline receptors (Chung et al. 2013; Tsai et al. 2014). In the present study, we found that allantoin could activate the I3 receptors to protect β-cells from the damage induced by STZ.
Diabetic disorders are associated with progressive β-cell failure and apoptosis (Eizirik & Mandrup-Poulsen 2001). STZ induced diabetes is well-established and accepted in studies of pathogenesis as well as the complication of diabetes (Szkudelski, 2001), and it has been widely used in experimental animals (Rees & Alcolado 2005) and cytotoxic effect of STZ in β-cells (Lenzen 2008). To mimic this disorder, we treated β-cells with STZ (5 mM) in medium containing 25 mM glucose for 6 h. Moreover, high glucose is known to increase pancreatic cell vulnerability to toxic damage by increasing the expression of potential autoantigens on the cell membrane surface (Mellado-Gil & Aguilar-Diosdado 2004). Therefore, we established a model that induced significant changes in β-cells, including the induction of an apoptotic response.

In the present study, we found that allantoin attenuated the damage induced by STZ in a dose-dependent manner, resulting in the reduction of STZ-induced β-cell apoptosis. Allantoin induced a significant decrease in caspase-3 expression and an increase in Bcl-2 expression detected by Western blotting. Caspases activation plays an important role in the execution phase of cell apoptosis (Jin & El-Deiry 2005; Lee et al. 2006), while Bcl-2 is considered to act as an anti-apoptotic protein that promotes cell survival (Vaux et al. 1988). Thus, allantoin can increase the survival rate of β-cells through improvement of apoptosis.

Imidazoline compounds have been suggested to induce insulin secretion from pancreatic β-cells through activation of the I3 receptors located on the β-cells (Tsai et al. 2014). In the presence of KU14R, I3 receptor antagonist, the protective effect induced by allantoin in β-cells was partially blocked. Flow cytometric analysis also supported this findings. As shown in Figure 4, cell viabilities were improved after allantoin treatment, and this effect was also suppressed by the blockade of I3 receptors using KU14R. As previously described, rats injected with a low dose of STZ exhibited higher blood glucose and lower plasma insulin levels (Tsai et al. 2014). Allantoin
improved the damaged function of \( \beta \)-cells in this animal model, which resulted in an increase of plasma insulin levels and a reduction of plasma glucose levels. This in vivo action of allantoin was also inhibited by KU14R to block the I3 receptors. Thus, the action of allantoin via the activation of I3 receptors was shown both in vivo and in vitro. Similar result was also observed in the action of canavanine (Yang et al. 2015).

Moreover, we found that the protective effect of allantoin was linked to the phospholipase C (PLC) pathway. In the presence of U73122, a well-known PLC inhibitor, the protective effect of allantoin was markedly reduced (Fig. 5). In theory, upon activation, PLC cleaves phosphatidylinositol 4,5-biphosphate into diacylglycerol and inositol 1,4,5-triphosphate, which may potentiate insulin secretion (Joslin & Kahn 2005). Whether this action is related to the protection of \( \beta \)-cells shall be investigated in future studies.

Additionally, several yam species (Dioscorea spp.) are also known to contain saponin and the aglycone portion of saponin called sapogenin, that are also proven to be beneficial in STZ induced diabetic rats (Omoruyi, 2008; Pessoa et al., 2015). Taken together, allantoin or yam (Dioscorea spp.) seems beneficial to treat and/or prevent the diabetes in the future.

Nevertheless, for the first time, we characterized the improvement of STZ-induced \( \beta \)-cell damage by allantoin via the I3 receptors both in vivo and in vitro.

**Conclusion**

Allantoin has the ability to increase \( \beta \)-cells viability and ameliorate \( \beta \)-cell damage through activation of the I3 receptors. Thus, allantoin and related analogs supplied as nutrients may be useful for the improvement of early stage of \( \beta \)-cell damage.
Acknowledgement

We thank all the staff members of the Institute of Laboratory Animal Sciences, Kagoshima University (Frontier Science Research Center) who kept the animals in good condition.
References

American Diabetes A. 2010. Diagnosis and classification of diabetes mellitus. Diabetes Care 33 Suppl 1:S62-69.

Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, and Butler PC. 2003. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110.

Cernea S. 2011. The role of incretin therapy at different stages of diabetes. Rev Diabet Stud 8:323-338.

Chang WC, Yu YM, Wu CH, Tseng YH, and Wu KY. 2005. Reduction of oxidative stress and atherosclerosis in hyperlipidemic rabbits by Dioscorea rhizome. Can J Physiol Pharmacol 83:423-430.

Chen MF, Tsai JT, Chen LJ, Wu TP, Yang JJ, Yin LT, Yang YL, Chiang TA, Lu HL, and Wu MC. 2014a. Antihypertensive action of allantoin in animals. Biomed Res Int 2014:690135.

Chen MF, Tsai JT, Chen LJ, Wu TP, Yang JJ, Yin LT, Yang YL, Chiang TA, Lu HL, and Wu MC. 2014b. Characterization of imidazoline receptors in blood vessels for the development of antihypertensive agents. Biomed Res Int 2014:182846.

Chen MF, Yang TT, Yeh LR, Chung HH, Wen YJ, Lee WJ, and Cheng JT. 2012. Activation of imidazoline I-2B receptors by allantoin to increase glucose uptake into C(2)C(1)(2) cells. Horm Metab Res 44:268-272.

Chung HH, Lee KS, and Cheng JT. 2013. Decrease of Obesity by Allantoin via Imidazoline I 1 - Receptor Activation in High Fat Diet-Fed Mice. Evid Based Complement Alternat Med 2013:589309.
Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, and Eizirik DL. 2005. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. *Diabetes* 54 Suppl 2:S97-107.

Dardonville C, and Rozas I. 2004. Imidazoline binding sites and their ligands: an overview of the different chemical structures. *Med Res Rev* 24:639-661.

Eizirik DL, and Mandrup-Poulsen T. 2001. A choice of death--the signal-transduction of immune-mediated beta-cell apoptosis. *Diabetologia* 44:2115-2133.

Ernsberger P, Graves ME, Graff LM, Zakieh N, Nguyen P, Collins LA, Westbrooks KL, and Johnson GG. 1995. I1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling. *Ann N Y Acad Sci* 763:22-42.

Head GA, and Mayorov DN. 2006. Imidazoline receptors, novel agents and therapeutic potential. *Cardiovasc Hematol Agents Med Chem* 4:17-32.

Jin Z, and El-Deiry WS. 2005. Overview of cell death signaling pathways. *Cancer Biol Ther* 4:139-163.

Joslin EP, and Kahn CR. 2005. *Joslin's diabetes mellitus*: Lippincott Williams & Willkins.

Lee MY, Lee NH, Jung D, Lee JA, Seo CS, Lee H, Kim JH, and Shin HK. 2010. Protective effects of allantoin against ovalbumin (OVA)-induced lung inflammation in a murine model of asthma. *Int Immunopharmacol* 10:474-480.

Lee WK, Abouhamed M, and Thevenod F. 2006. Caspase-dependent and -independent pathways for cadmium-induced apoptosis in cultured kidney proximal tubule cells. *Am J Physiol Renal Physiol* 291:F823-832.

Lenzen S. 2008. The mechanisms of alloxan- and streptozotocin-induced diabetes. *Diabetologia* 51:216-226.
Li JX, and Zhang Y. 2011. Imidazoline I2 receptors: target for new analgesics? *Eur J Pharmacol* 658:49-56.

Lin KC, Yeh LR, Chen LJ, Wen YJ, Cheng KC, and Cheng JT. 2012. Plasma glucose-lowering action of allantoin is induced by activation of imidazoline I-2 receptors in streptozotocin-induced diabetic rats. *Horm Metab Res* 44:41-46.

Liu Z, Stanojevic V, Brindamour LJ, and Habener JF. 2012. GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic beta-cells from glucolipotoxicity. *J Endocrinol* 213:143-154.

Lui TN, Tsao CW, Huang SY, Chang CH, and Cheng JT. 2010. Activation of imidazoline I2B receptors is linked with AMP kinase pathway to increase glucose uptake in cultured C2C12 cells. *Neurosci Lett* 474:144-147.

Luo J, Hu Y, Kong W, and Yang M. 2014. Evaluation and structure-activity relationship analysis of a new series of arylnaphthalene lignans as potential anti-tumor agents. *PLoS One* 9:e93516.

Mandrup-Poulsen T. 2001. beta-cell apoptosis: stimuli and signaling. *Diabetes* 50 Suppl 1:S58-63.

Mellado-Gil JM, and Aguilar-Diosdado M. 2004. High glucose potentiates cytokine- and streptozotocin-induced apoptosis of rat islet cells: effect on apoptosis-related genes. *J Endocrinol* 183:155-162.

Omoruyi FO. 2008. Jamaican bitter yam sapogenin: Potential mechanisms of action in diabetes. *Plant Foods for Human Nutrition* 63:135–140.

Pessoa LR, Rêgo TDS, Asht S, Cabral I, Fortunato RS, Barreto M, Correia-santos AM, Alberto C, and Boaventura GT. 2015. Serum and liver lipids distributions in streptozotocin induced diabetic
rat treated with diet containing Yam (Dioscorea bulbifera) flour. *Nutricion Hospitalaria* 31:1647–1653.

Rees DA, and Alcolado JC. 2005. Animal models of diabetes mellitus. *Diabet Med* 22:359-370.

Sagara K, Ojima M, Suto K, and Yoshida T. 1989. Quantitative determination of allantoin in Dioscorea rhizome and an Oriental pharmaceutical preparation, hachimi-gan, by high-performance liquid chromatography. *Planta Med* 55:93.

Sato K, Iemitsu M, Aizawa K, and Ajisaka R. 2009. DHEA improves impaired activation of Akt and PKC zeta/lambda-GLUT4 pathway in skeletal muscle and improves hyperglycaemia in streptozotocin-induced diabetes rats. *Acta Physiol (Oxf)* 197:217-225.

Shewade YM, Umrani M, and Bhonde RR. 1999. Large-scale isolation of islets by tissue culture of adult mouse pancreas. *Transplantation Proceedings* 31:1721-1723.

Szkudelski T. 2001. The Mechanism of Alloxan and Streptozotocin Action in B Cells of the Rat Pancreas.

Tsai CC, Chen LJ, Niu HS, Chung KM, Cheng JT, and Lin KC. 2014. Allantoin activates imidazoline I-3 receptors to enhance insulin secretion in pancreatic beta-cells. *Nutr Metab (Lond)* 11.

Vaux DL, Cory S, and Adams JM. 1988. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. *Nature* 335:440-442.

Wang T, Choi RC, Li J, Bi CW, Ran W, Chen X, Dong TT, Bi K, and Tsim KW. 2012. Trillin, a steroidal saponin isolated from the rhizomes of Dioscorea nipponica, exerts protective effects against hyperlipidemia and oxidative stress. *J Ethnopharmacol* 139:214-220.
Yang TT, Chiu NH, Chung HH, Hsu CT, Lee WJ, and Cheng JT. 2012. Stimulatory effect of allantoin on imidazoline I(1) receptors in animal and cell line. *Horm Metab Res* 44:879-884.

Yang TT, Niu HS, Chen LJ, Ku PM, Lin KC, Cheng JT. 2015. Canavanine induces insulin release via activation of imidazoline I_3_ receptors. *Clinical and Experimental Pharmacology and Physiology* 42:263–268.
Figure legend

Figure 1. ApoTox-Glo triplex assay showing the viability (A), cytotoxicity (B), and apoptosis (C) of β-cells treated with 5 mM streptozocin (STZ), 5 mM STZ + 1 µM allantoin, 5 mM STZ + 10 µM allantoin, and 5 mM STZ + 100 µM allantoin (n = 6 for each group). Data are presented as the mean ± SE. *P < 0.05, **P < 0.01.

Figure 2. ApoTox-Glo Triplex assay showing the viability (A), cytotoxicity (B), and apoptosis (C) of β-cells in rats treated with 5 mM streptozocin (STZ), 5 mM STZ + 100 µM allantoin, 5 mM STZ + 1 µM KU14R + 100 µM allantoin (n = 6 for each group). Data are presented as the mean ± SE. **P < 0.01.

Figure 3. Cell viability image of β-cell after treatment with 5 mM streptozocin (STZ), 5 mM STZ + 100 µM allantoin, 5 mM STZ + 1 µM KU14R + 100 µM allantoin. Allantoin greatly improved the viability of STZ-induced β-cells apoptosis.

Figure 4. Flow cytometry of apoptotic cells. Samples were incubated with FITC-labeled Annexin-V and propidium iodide. Number at the corner represent the percentage of cells found in each quadrant.

Figure 5. ApoTox-Glo Triplex assay showing the viability (A), cytotoxicity (B), and apoptosis (C) of β-cells in rats treated with 5 mM streptozocin (STZ), 5 mM STZ + 100 µM allantoin, 5 mM STZ + 1 µM U73122 + 100 µM allantoin (n = 6 for each group). Data are presented as the mean ± SE. **P < 0.01.
Figure 6. Western blotting analysis of the expression levels of caspase-3 and Bcl-2. The expression level of caspase-3 was reduced by allantoin (A), while Bcl2 expression was increased (B) (n = 6 for each group). Data are presented as the mean ± SE. *P < 0.05, **P < 0.01.

Figure 7. Effects of allantoin and KU14R on blood glucose levels in streptozotocin (STZ) -treated rats. STZ-treated rats were daily treated with 10 mg/kg allantoin and 8 mg/kg KU14R. Plasma glucose levels were measured daily for 8 days (n = 8 for each group). Values are presented as the mean ± SE. *P < 0.05 and **P < 0.01 for the difference between STZ and STZ + Allantoin + KU14R. #< 0.05 for the difference between STZ + Allatoin and STZ + Allantoin + KU14R.

Figure 8. Effects of allantoin and KU14R on plasma insulin levels in streptozotocin (STZ) -treated rats. STZ-treated rats were daily treated with 10 mg/kg allantoin and 8 mg/kg KU14R. Plasma insulin levels were measured on day 0,4,6,8 (n = 8 for each group). Values are presented as the mean ± SE. **P < 0.01 for the difference between STZ and STZ + Allantoin or STZ + Allantoin + KU14R. #< 0.05 and ## < 0.01 for the difference between STZ + Allatoin and STZ + Allantoin + KU14R.
Figure 1

ApoTox-Glo triplex assay showing the viability (A), cytotoxicity (B), and apoptosis (C) of β-cells treated with 5 mM streptozotocin (STZ), 5 mM STZ + 1 μM allantoin, 5 mM STZ + 10 μM allantoin, and 5 mM STZ + 100 μM allantoin (n = 6 for each group). Data are presented as the mean ± SE. *P < 0.05, **P < 0.01.
Figure 2

ApoTox-Glo Triplex assay showing the viability (A), cytotoxicity (B), and apoptosis (C) of β-cells in rats treated with 5 mM streptozotocin (STZ), 5 mM STZ + 100 µM allantoin, 5 mM STZ + 1 µM KU14R + 100 µM allantoin (n = 6 for each group). Data are presented as the mean ± SE. **P < 0.01.
Figure A: Viability Fluorescence (RFU) with different treatments.

Figure B: Cytotoxicity Fluorescence (CFU) with different treatments.

Figure C: Apoptosis Fluorescence (AFU) with different treatments.

| Treatment       | STZ 5mM | Allantoin 100µM | KU14R 1µM |
|-----------------|---------|-----------------|-----------|
| -               | -       | -               | -         |
| +               | +       | +               | +         |
| +               | +       | +               | +         |

** indicates statistical significance.
Figure 3

Cell viability image of β-cell after treatment with 5 mM streptozotocin (STZ), 5 mM STZ + 100 µM allantoin, 5 mM STZ + 1µM KU14R + 100 µM allantoin. Allantoin greatly improved the viability of STZ-induced β-cells apoptosis.
Flow cytometry of apoptotic cells. Samples were incubated with FITC-labeled Annexin-V and propidium iodide. Number at the corner represent the percentage of cells found in each quadrant.
Figure 5

ApoTox-Glo Triplex assay showing the viability (A), cytotoxicity (B), and apoptosis (C) of β-cells in rats treated with 5 mM streptozotocin (STZ), 5 mM STZ + 100 µM allantoin, 5 mM STZ + 1 µM U73122 + 100 µM allantoin (n = 6 for each group). Data are presented as the mean ± SE. **P < 0.01.
Figure 6

Western blotting analysis of the expression levels of caspase-3 and Bcl-2. The expression level of caspase-3 was reduced by allantoin (A), while Bcl2 expression was increased (B) (n = 6 for each group). Data are presented as the mean ± SE. *P < 0.05, **P < 0.01.
A

Caspase-3
Actin

Arbitrary unit
0 0.5 1 1.5

STZ 5mM - + + +
Allantoin 100μM - - + +
KU14R 1μM - - + +

B

Bcl2
Actin

Arbitrary unit
0 0.5 1 1.5

STZ 5mM - + + +
Allantoin 100μM - - + +
KU14R 1μM - - + +
Figure 7

Effects of allantoin and KU14R on blood glucose levels in streptozotocin (STZ)-treated rats. STZ-treated rats were daily treated with 10 mg/kg allantoin and 8 mg/kg KU14R. Plasma glucose levels were measured daily for 8 days (n = 8 for each group). Values are presented as the mean ± SE. *P < 0.05 and **P < 0.01 for the difference between STZ and STZ + Allantoin + KU14R. # < 0.05 for the difference between STZ + Allatoin and STZ + Allantoin + KU14R.
Figure 8

Effects of allantoin and KU14R on plasma insulin levels in streptozotocin (STZ) -treated rats. STZ-treated rats were daily treated with 10 mg/kg allantoin and 8 mg/kg KU14R. Plasma insulin levels were measured on day 0,4,6,8 (n = 8 for each group). Values are presented as the mean ± SE. **$P < 0.01$ for the difference between STZ and STZ + Allantoin or STZ + Allantoin + KU14R. # $< 0.05$ and ## $< 0.01$ for the difference between STZ + Allatoin and STZ + Allantoin + KU14R.